M Fukuoka
Overview
Explore the profile of M Fukuoka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
421
Citations
3066
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Polak S, Beever L, Wade A, Fukuoka M, Worth A
N Z Vet J
. 2023 Sep;
72(1):17-27.
PMID: 37772312
Aim: To biomechanically compare the bending stiffness, strength, and cyclic fatigue of titanium additively manufactured (AM) and conventionally manufactured (CM) limited contact plates (LCP) of equivalent dimensions using plate-screw constructs....
2.
Tsukuda H, Tsuya A, Hasegawa Y, Ota T, Fukuoka M
QJM
. 2022 Jan;
115(3):177-178.
PMID: 35094089
No abstract available.
3.
Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I, Yamanaka T, et al.
Lung Cancer
. 2020 Dec;
151:20-24.
PMID: 33279874
Objectives: The JO25567 randomized Phase II study demonstrated a statistically significant progression-free survival (PFS) benefit with erlotinib plus bevacizumab compared with erlotinib monotherapy in chemotherapy-naïve Japanese patients with epidermal growth...
4.
Fullard L, Breard E, Davies C, Godfrey A, Fukuoka M, Wade A, et al.
Proc Math Phys Eng Sci
. 2019 Feb;
475(2221):20180462.
PMID: 30760953
The dynamics of granular flow in a rectangular silo with two symmetrically placed exit openings is investigated using particle image velocimetry (PIV), flow rate measurements and discrete element modelling (DEM)....
5.
Yoshioka H, Katakami N, Okamoto H, Iwamoto Y, Seto T, Takahashi T, et al.
Ann Oncol
. 2017 Apr;
28(2):285-291.
PMID: 28426104
Background: Amrubicin is approved for treating non-small-cell lung cancer (NSCLC) and small-cell lung cancer. However, no direct comparisons between amrubicin and docetaxel, a standard treatment for NSCLC, have been reported....
6.
Emoto-Yamamoto Y, Iida S, Kawanishi T, Fukuoka M
J Clin Pharm Ther
. 2014 Nov;
40(2):232-9.
PMID: 25402940
What Is Known And Objective: This study aimed to elucidate the pharmacokinetics of erlotinib in Japanese patients with advanced non-small cell lung cancer (NSCLC) and to investigate the relationship between...
7.
Eto K, Kawakami H, Kuwatani M, Kudo T, Abe Y, Kawahata S, et al.
Br J Cancer
. 2013 Mar;
108(7):1488-94.
PMID: 23492684
Background: Pancreatic ductal carcinoma (PDC) is one of the most lethal human carcinomas. Expression patterns of some genes may predict gemcitabine (GEM) treatment efficacy. We examined predictive indicators of survival...
8.
Soria J, Mauguen A, Reck M, Sandler A, Saijo N, Johnson D, et al.
Ann Oncol
. 2012 Nov;
24(1):20-30.
PMID: 23180113
Background: Previous studies have demonstrated the efficacy and safety of bevacizumab in the treatment of non-small-cell lung cancer (NSCLC). Methods: Summary data from randomised trials comparing first-line bevacizumab plus platinum-based...
9.
Niho S, Ohe Y, Ishikura S, Atagi S, Yokoyama A, Ichinose Y, et al.
Ann Oncol
. 2012 Feb;
23(9):2253-2258.
PMID: 22357446
Background: We conducted a feasibility study of induction chemotherapy followed by gefitinib and thoracic radiotherapy (TRT) for unresectable locally advanced adenocarcinoma of the lung. Patients And Methods: Patients received induction...
10.
Ohno A, Hirashima T, Kubo A, Masuda N, Takada M, Fujiwara H, et al.
Int J Oncol
. 2011 May;
10(3):521-8.
PMID: 21533407
To investigate the role of p53 abnormalities in predicting the survival of patients with non-small cell lung cancer (NSCLC), polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and immunohistochemical analyses were...